Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Jiangsu Bioperfectus Technologies Co., Ltd. specializes in the development and manufacturing of molecular diagnostic products, particularly in the fields of infectious diseases and oncology. The company leverages its proprietary technologies to maintain a competitive edge in the rapidly evolving Chinese biotechnology market, focusing on high-throughput testing solutions.
Bioperfectus generates revenue primarily through the sale of its molecular diagnostic kits, which are used in hospitals and laboratories across China. The company benefits from strong pricing power due to its proprietary technology and established brand reputation in the diagnostics sector. Additionally, it engages in R&D collaborations that provide supplemental revenue.
Regulatory approvals for new diagnostic products
Partnerships with hospitals and healthcare providers
Market demand for COVID-19 and other infectious disease testing
Advancements in molecular diagnostic technologies
Technological disruption from new diagnostic technologies
Regulatory changes affecting product approvals and market access
Increased competition from domestic and international biotech firms
Potential for price erosion in the diagnostic kit market
Negative operating margins leading to cash flow challenges
Dependence on external funding for R&D projects
moderate - The biotechnology sector is somewhat insulated from economic downturns, but funding for R&D and healthcare spending can be affected by GDP fluctuations.
Interest rates can impact Bioperfectus through the cost of financing for R&D and capital expenditures, potentially affecting growth and valuation multiples.
minimal - The company's low debt-to-equity ratio indicates limited reliance on external financing.
growth - Investors looking for exposure to the expanding biotechnology sector and innovative diagnostic solutions.
high - The stock has shown significant price fluctuations, particularly in response to regulatory news and market developments.
